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ABSTRACT 
 
ANALYSIS OF LSAMP GENE AS A TUMOR SUPPRESSOR IN 
NEUROBLASTOMA 
 
ATIL ÇAĞDAŞ SAYDERE 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. M. Cengiz Yakıcıer 
December 2009, 59 pages 
 
Neuroblastoma constitutes approximately 10 % of all childhood tumors with a 
worldwide considerable morbidity and mortality. Frequently, in children under the 
age of 1, it can spontaneously regress and transform into a benign tumor. However, 
in children older than age of 1 the disease often behaves aggressively and 
metastasizes to other organs. This unpredictable behavior of unknown origin makes 
therapeutic applications ineffective.  
 
Limbic system associated membrane protein gene (LSAMP) functions in neurite 
growth, axonal guidance and acts as a cell adhesion and recognition molecule. 
Recent studies revealed its association to several cancer types and proposed a 
potential tumor suppressor role. Markers in the LSAMP gene region were also shown 
to be homozygously deleted in neuroblastoma. In the framework of this study, we 
investigated LSAMP gene in respect of its potential tumor suppressor role in 
neuroblastoma. 6 clinical patient samples and 2 neuroblastoma cell lines were 
studied via PCR methodology to detect any loss in LSAMP gene. 
Immunohistochemistry (IHC) was applied to 6 neuroblastoma tissue sections to 
determine protein level changes of LSAMP. Moreover, expression analysis in a set of 
brain tumors was performed. As a result of these efforts, one possible LOH and one 
homozygous deletion in two different patients were observed. Low levels of LSAMP 
protein in all of the tumor samples compared to controls were recorded.  
iii 
 
 
Downregulation of LSAMP in brain tumors was detected. Based on these results, 
LSAMP is suggested as a candidate tumor suppressor in neuroblastoma and in 
broader aspect for nervous system tumors.   
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ÖZET 
 
LSAMP GENĐNĐN NÖROBLASTOMALARDA TÜMÖR BASKILAYICI 
OLARAK ANALĐZĐ 
 
ATIL ÇAĞDAŞ SAYDERE 
Moleküler Biyoloji ve Genetik Bölümü Yüksek Lisansı 
Danışman: Assist. Prof. M. Cengiz Yakıcıer 
Aralık 2009, 59 sayfa 
 
Nöroblastoma dünya çapında önemli morbidite ve mortaliteye sahip olup tüm 
çocukluk çağı tümörlerinin yaklaşık %10’unu oluşturmaktadır. Sıklıkla, 1 yaş 
altındaki çocuklarda, kendiliğinden gerileyerek ve iyi huylu bir tümör haline 
dönüşmektedir. Ancak, 1 yaş üzeri çocuklarda genellikle agresif davranır ve diğer 
organlara metastaz olur. Kaynağı bilinmeyen bu beklenmedik davranış tedavi 
uygulamalarını etkisiz hale getirir. 
 
Kromozom bölgesi 3q13.3 üzerinde bulunan limbik sistem ilişkili membran proteini 
geni (LSAMP) sinir hücrelerinin büyümesinde ve akson rehberliğinde görevlidir. 
Ayrıca, bir adezyon ve hücreler arası tanıma molekülü gibi davranır. Son yıllarda 
yapılan çalışmalarda çeşitli kanser türleriyle ilişkisi gösterilmiş ve potansiyel bir 
tümör baskılayıcı rolü önerilmiştir.Ayrıca LSAMP geni bölgesindeki markörlerin 
homozigot kayıplara uğradığı gösterilmiştir. Bu çalışma çerçevesinde, LSAMP 
geninin nöroblastomada olası bir tümör baskılayıcı rolü araştırıldı. 6 klinik hasta 
numunesi ve 2 nöroblastoma hücre hattı PCR yöntemi ile LSAMP gen kaybını ortaya 
çıkarmak için çalışıldı. 6 nöroblastoma doku kesitinde LSAMP protein düzeyindeki 
değişiklikleri belirlemek için immunohistokimya (ĐHK) uygulandı. Bir grup beyin 
tümöründe ifade analizi yapıldı. Đki farklı hastada bu çabalar, olası bir LOH ve bir 
homozigot kayıp sonuçları olarak gözlemlendi. Kontrol grubuna göre tüm tümör 
örneklerinde LSAMP proteinin düşük seviyeleri kaydedildi. Beyin tümörlerinde  
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LSAMP ifadesinde azalma belirlendi.Bu sonuçlara dayanarak, LSAMP tümör 
baskılayıcı adayı olarak nöroblastomada ve daha geniş anlamda sinir sistemi 
tümörlerinde önerilmektedir. 
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1 INTRODUCTION 
 
Neuroblastoma was first identified and characterized as a tumor by Virchow in 1864 
and by Marchand in 1891, respectively (Hayes PA, 1989; Voute PA, 1984). Since 
their identification, the tumor has succeeded to stimulate interests of the researchers 
by its distinct characteristics. The neuroblastoma tumor tissues either regress 
spontaneously as observed especially in infants or they mature into benign tumors 
called ganglioneuroma (Brodeur and Castleberry, 1993). However, it is almost 
impossible to predict the behavior and most children over 1 year of age already have 
tumor metastasized into other organs at the time of diagnosis (Brodeur, 2003). The 
heterogeneous behavior of the disease prevented comprehensive clinical studies and 
resulted in poor prognosis until studying the tumor with the tools of molecular 
genetics and biochemistry.   
 
1.1 Epidemiology 
 
Neuroblastoma is the most common extracranial solid tumor seen in pediatric 
population. It accounts for 8-10 % among all childhood cancers and it is the most 
common diagnosed cancer type for infants (Gurney et al., 1997). Neuroblastoma is 
diagnosed in United States and Canada one case in 7000 live births per year and 
approximately 700 new cases per year are observed (Brodeur and Castleberry, 1993). 
In Europe compared to USA and Canada more than two times higher, 1500 cases 
occur per year (Gao et al., 1997; Spix et al., 2006). Among all cancers diagnosed in 
European and USA infants, neuroblastoma accounts for about 28% (Gurney et al., 
1997; Spix et al., 2006). Almost the same incidence rate for the rest of the world 
according to reported cases are observed (Brodeur and Castleberry, 1993).  The 
incidence has a peak before the age 1 and the median age of the patients diagnosed 
with neuroblastoma is 18 months (Brodeur and Castleberry, 1993; Heck et al., 2009).  
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There is an equivalent or slightly higher prevalence of the disease in boys than girls 
in most countries. There is no difference between the ethnic groups for the incidence 
of the disease (Gao et al., 1997; Ries et al., 2005; Spix et al., 2006).  
 
1.2 Pathogenesis and Aetiology 
 
1.2.1 Pathogenesis 
 
Neuroblastoma is a malignant tumor originating from the neural crest cells which 
arise in the third to fourth week of embryonic development. Some pluripotent cells or 
neuroblasts of this layer can form the components of the sympathetic nervous system 
by differentiating into sub populations (Fig.1). These cells invaginate and migrate 
along the neuraxis and accumulate in sympathetic ganglia, adrenal medulla and 
different sites of the bone and soft tissue (Gray H, 2005). The distribution of these 
cells into the sub regions of the sympathetic system correlates with the primary 
diagnosis sites of the neuroblastoma. In most cases, approximately 40%, the origin 
side of the tumor is one of the adrenal glands or in other cases it is observed in the 
chest, abdomen and pelvic (Gao et al., 1997; Ries et al., 2005).  
 
Among other known human malignancies, neuroblastoma distinguishes itself by an 
enigmatic behavior in which some cells undergo a spontaneous regression from a 
malign state to a benign state while others persistently progress (Brodeur and Maris, 
2006) . The tumor may undergo differentiation and/or apoptosis in patients under 1 
year of age in contrast with patients older than 1 year of age where it shows an 
aggressive behavior and leads to death (Brodeur, 2003; Nakagawara, 1998).   
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Figure 1: The lineages derived from neural crest and the origin of neuroblastoma. 
(Nakagawara and Ohira, 2004) 
 
 
In order to facilitate diagnosis and prognosis of the disease a classification system 
called Shimada System which classify patients into three risk groups; low, 
intermediate and high was created in 1984  (Shimada et al., 1984). It was used to 
determine the curability of the patient ; low risk and intermediate risk patients which 
usually comprise infants have a higher chance of cure compared to high risk group 
patients who have poor diagnosis and outcome (Maris, 2005). The majority of the 
patients older than 18 months have the disease metastasized to lymph nodes, liver, 
bone and bone marrow but despite the intensive therapies followed by autologous 
bone marrow transplant, more than half of the patients cannot survive (Spix et al., 
2006) 
 
The recent advances allowed the disease to be re-classified into different stages and 
risk groups by using factors like differentiation state, MYCN amplification, age, 
Schwannian stroma content and mitosis-karyorrhexis index at the time of diagnosis 
(Maris et al., 2007; Shimada et al., 1999). The efforts of International Neuroblastoma 
Risk Group (INRG) developed a classification system in modifying the previously 
used Schimada System. According to this classification schema the tumors are 
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categorized into three risk groups; low, intermediate and high and different stages of 
the disease is defined from 1 to 4 where 4 represents the metastasized tumor (Maris 
et al., 2007). One stage called 4s which is special for the patients younger than 1 year 
of age and seen nearly 5% of the patients is also described. In this case, the tumor is 
spread to liver, skin or bone marrow but show a spontaneous regression (D'Angio et 
al., 1971). 
 
1.2.2 Aetiology 
 
The sporadic occurrence of the disease makes it challenging to study and there is not 
much known about the aetiology of the disease but as a common reason in 
tumorigenesis environmental effects are thought to play a role for the development of 
the disease (Brodeur, 2003).  Among these environmental factors, using medications 
like pain killers, exposure to electro-magnetic fields, the use of sex hormones and 
vitamins has been hypothesized for the aetiology of the disease (Carachi, 2002). In 
recent studies maternal alcohol consumption, paternal exposure to nonvolatile and 
volatile hydrocarbons, wood dusts and solders, use of diuretics and low birth weight 
are suggested to be positively associated with the disease (Heck et al., 2009). 
  
1.3 Genetic Aberrations in Neuroblastoma 
 
The molecular pathology of neuroblastoma is still poorly understood. However, 
common genetic alterations have been observed in patients diagnosed with 
neuroblastoma and these alterations are used for risk stratification. The best 
characterized genetic alterations include amplification of the proto-oncogene MYCN, 
gain of chromosome arm 17q and losses of 1p, 3p, and 11q. Based on these 
aberrations, neuroblastoma is classified into three genetic sub groups. Beside MYCN 
on chromosome arm 2p which was previously identified as an oncogene, further 
efforts are focused on identifying any candidate tumor suppressor genes or 
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oncogenes located within the regions of loss or gain, respectively. Until now, no new 
genes that drive neuroblastoma development and progression have been successfully 
characterized.  
 
1.3.1 Genomic Gains: 
 
1.3.1.1 Ploidy: 
 
DNA content is an important prognostic marker for the neuroblastoma patients. 
Although in most cases tumors have diploid karyotypes, a distinct case for lower 
stage neuroblastoma patients exist as they may often have hyperdiploid or near 
triploid (Kaneko et al., 1987).  Thus, during prognosis the karyotype analysis of 
neuroblastomas is performed to determine the ploidy status and having near-triploidy 
is more favorable for the patients associated with longer survival. However, it is 
more significant for infants compared to children older than 1 year of age. The 
reason behind is that less aggressive tumlors have a major defect in mitosis which 
results in whole chromosomal gains and losses where aggressive tumors additionally 
imperfect in genomic stability which ends in structural rearrangements (Brodeur, 
2003; Look et al., 1984).   
 
1.3.1.2 MYCN Genomic Amplification: 
 
The well known associated marker of neuroblastoma is the genomic amplification of 
MYCN which occurs in 20% of patients and strongly correlates with higher stages of 
the disease and poor outcome (Brodeur and Seeger, 1986; Schwab et al., 2003; 
Shimada et al., 1999). MYCN gene is located on chromosome 2p24 locus and it was 
identified in neuroblastoma cell lines as an amplified DNA sequence homologous to 
proto-oncogene c-MYC. The amplified region that contains MYCN chromosome 
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2p24 locus form double minute chromosomes (DM) and  they are integrated linearly 
to random chromosomes resulting in homogenously staining regions (HSR) that may 
contain copies up to 500 (Schwab et al., 1983) (Fig. 2). Rather than a mutation in this 
amplified region, it is suggested that overexpression of wild type MYCN leads to 
tumorigenesis as overexpressing MYCN in neural crest of transgenic mice can 
develop neuroblastomas and decreasing MYCN mRNA levels by using antisense 
MYCN can induce differentiation of human neuroblastoma cell lines (Schmidt et al., 
1994; Weiss et al., 1997).   
 
 
 
Figure 2: MYCN amplification pattern; A) Amplification patterns of double minutes 
(DM) and homogenously staining regions (HSR) are observed in solid tumors 
(Albertson et al., 2003) B) FISH image of MYCN amplification presented in DM (Maris 
et al., 2007) C) HSR for MYCN amplification in neuroblastoma cell line NGP (Schwab 
et al., 2003) 
 
1.3.1.3 Gain of 17q: 
 
Extra copies of chromosome arm 17q are observed in more than half of the 
neuroblastomas. The gain of 17q may occur independently but more often results 
from unbalanced translocation events with chromosome 1p or 11q and associated 
with poor outcome (Bown et al., 1999; Caron, 1995). The gene dosage effect of one 
or more genes in extra copies is thought to provide a selective advantage to cells 
resulting in aggressive phenotype (Lastowska et al., 2002). Although there is no 
exact site of breakpoint, the region of 17q22-qter has been suggested as carrying 
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genes that promotes cell survival (Van Roy et al., 1997). The most of the genes have 
not been identified yet but among the known genes overexpression of BIRC5 
(survivin) which encodes an inhibitor of apoptosis proteins has been proposed for the 
reason of aggressive phenotype seen in gain of 17q (Islam et al., 2000). In some 
cases segmental gains of 1q, 5q and 18q are also observed but their characterizations 
still remain in question (Schwab et al., 2003). 
 
1.3.2 Genetic Deletions and Allelic Losses: 
 
1.3.2.1 Loss of 1p: 
 
The most common loss of heterozygosity (LOH) seen in neuroblastoma patients is 
the loss of 1p which is seen about 30-35% of the cases (Brodeur, 2003). Deletions in 
chromosome region 1p correlate with the advanced stages of the disease and 
frequently associated with MYCN amplification and unbalanced translocation with 
17q, t (1; 17) (Caron, 1995).  Studies identified the smallest region that overlaps in 
tumors with loss of 1p as the locus 1p36 and loss of putative tumor suppressors in 
this region is thought to be responsible for disease progression (Caron et al., 2001). 
However, there is no consensus about the role of this locus independent of other 
factors as there are inconsistent data presented by different groups. 
 
1.3.2.2 Loss of 11q: 
 
Approximately 35% of the diagnosed neuroblastoma patients have deletions at 
chromosome region 11q. Translocations involving 11q21 and 11q22, deletion at 
11q23, inversion at 11q21-11q23 and allelic losses are observed (Brodeur and Maris, 
2006). In most of the cases allelic losses are reported and it is negatively correlated 
with MYCN amplification. Deletion in 11q is frequently found in neuroblastomas 
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without MYCN amplification (Guo et al., 1999; Plantaz et al., 2001). However, the 
loss at this region associates with the advanced stages of the disease and poor 
prognosis. The existence of tumor suppressor genes in this region is thought to be 
responsible for malignant progression upon inactivation by allelic losses in MYCN 
single copy neuroblastomas (van Noesel and Versteeg, 2004). 
 
1.3.2.3 Losses at Other Chromosomes:  
 
Beside chromosome regions 1p and 11q, allelic losses at chromosome arms 2q, 3p, 
4p, 9p.12p, 14q, 15q, 16p and 19q are observed in lower frequencies. Several genes 
are identified in these regions as tumor suppressors or important regulators of 
cellular functions, but further investigation are needed for their prognostic 
significance (Table 1).   
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Chromosomal Locus Gene Name Gene Function 
1p36.2-p36.3 ? Tumor suppressor 
1p13 NGF Neurotrophin ligand for NTRKI 
1q23-q31 NTRK1 (TRK-A) Receptor tyrosine kinase 
2p12-13 MAD May regulate MYCN 
2p241 MYCN Proto-oncogene 
2p24 DDXI RNA helicase/oncogene 
3p ? Tumor suppressor 
4p ? Tumor suppressor 
7q21 PGY1 (MDR1) Multi drug resistance 
9q22.1 NTRK2 (TRK-B) Receptor tyrosine kinase 
11 p13 CD44 Integrin/metastasis suppression 
11 p13 BDNF Neurotrophin ligand for NTRKI 
11 q23 ? Tumor suppressor 
12p1 3 NTF3 (NT-3) Neurotrophin ligand for NTRK3 
14q23 MAX Regulates MYCN 
14q23-qter ? Tumor suppressor 
15q24-q25 NTRK3 (TRK-C) Receptor tyrosine kinase 
16p13.1 MRP Multi drug resistance 
17q22 NMEI Nucleoside kinase/metastasis suppression 
17q23-qter ? Oncogene 
18q21.1 DCC Tumor suppressor 
18q21 3 BCL2 Apoptosis suppression 
19 NTF4 (NT-4) Neurotrophin ligand for NTRK2 
 
Table 1: Proven or speculated chromosomal loci involved in neuroblastoma 
tumorigenesis (Maris and Matthay, 1999) 
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1.3.3 Abnormal Expression of Neurotrophin Receptors: 
 
Neurotrophins are essential soluble factors needed during neural development and 
majorly include nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). Neuroblastomas as 
originating from neural crest have alterations in normal neural development pathway 
resulting in malignant transformation (Fig.3). However, in cases of spontaneous 
regression where the cells start to differentiate and apoptosis takes place, the 
recovery of neuronal development pathway occurs (Maris and Matthay, 1999). The 
signaling cascades are regulated through the Trk family of tyrosine kinases and 
TRKA, TRKB and TRKC have been defined as key receptors in this pathway. Specific 
receptor–ligand interactions occur; TRKA is the receptor for ligand NGF, TRKB 
serves for both BDNF and NT-4, and TRKC is the receptor for NT-3 (Nakagawara 
and Brodeur, 1997). The expression of TRKA is highly associated with favorable 
tumors and spontaneous regression where expression of TRKB is usually observed in 
aggressive tumors. The TRKB/BDNF signaling promotes cell survival enhancing 
angiogenesis and drug resistance. TRKC is also found expressed in lower stage 
tumors and is not expressed in MYCN amplified tumors (Matsumoto et al., 1995; 
Nakagawara, 1998). 
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Figure 3: Schematic presentation of genetic alterations in neuroblastoma and 
classification into different types (Maris and Matthay, 1999) 
 
1.4 LSAMP gene: 
 
LSAMP (Limbic System Associated Membrane Protein) encodes a neuronal surface 
glycoprotein protein and belongs to a family of genes called IgLON consisting of 
LSAMP (LAMP), OPCML/OBCAM (Opioid Binding Protein/Cell Adhesion 
Molecule Like), NTM (Neurotrimin) and NEGR1/KILON (Neuronal Growth 
Regulator 1) (Funatsu et al., 1999; Pimenta et al., 1995).  The IgLONs are identified 
as immunoglobulin subfamily of glycosylphosphatidylinositol-anchored cell 
adhesion molecules. The expressions of these genes are distributed in cortical and 
subcortical regions of the limbic system (Levitt, 1984; Struyk et al., 1995). During 
nervous system development, specific connections between neuronal cell populations 
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must be established correctly for proper growth and the axonal targeting molecules 
play a major role during this process. LSAMP together with other IgLONs is highly 
conserved among higher organisms and it mediates neuronal growth and axon 
targeting as well as acting in cell-cell recognition and cell adhesion (Zhukareva and 
Levitt, 1995).  
 
LSAMP is located on chromosome 3q13.31-q21 locus in the human genome (Fig.4) 
(Pimenta et al., 1998). It has seven exons with six alternative forms identified 
recently and encodes a plasma membrane protein with three Ig-like C2 type 
(immunoglobulin-like) domains and one glycosylphosphatidylinositol anchor. 
Microarray data reveal that LSAMP is highly expressed in cortical and subcortical 
regions of limbic system as well as tissues of parasympathetic and sympathetic 
nervous system (Fig.5). Markers in this region were also shown to be homozygously 
deleted in neuroblastoma cell lines (Caren et al., 2008). 
 
 
 
 
Figure 4: Location of LSAMP gene in long arm of chromosome 3. 
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Figure 5: Expression of LSAMP in different tissues (Data from Genomics Institute of 
the Novartis Research Foundation) 
 
 
14 
 
 
Until recently, there was not any data associating LSAMP to cancer and suggesting it 
as a tumor suppressor gene. However, low expression and polymorphism of LSAMP 
was found to be associated with behavioral disorders like hyperactivation, anxiety 
and panic in studies done with mice (Catania et al., 2008; Koido et al., 2006; Maron 
et al., 2006). Moreover, a study by Must et al. (2008) correlated LSAMP 
polymorphism to completed male suicide (Must et al., 2008). Wang. et al. (2008) 
proposed that genetic variations in LSAMP are associated with left main coronary 
artery disease (Wang et al., 2008) 
 
The first hypothesis for LSAMP to be a tumor suppressor gene came from the study 
of Chen et al. (2003) in familial clear cell renal cell carcinoma (CCRCC) (Chen et 
al., 2003). A translocation, t (1; 3), involving NORE1 and LSAMP as breakpoint 
spanning genes was identified in CCRCC. Although no mutation was observed for 
LSAMP, the promoter of LSAMP was found as hypermethylated and silenced in 
CCRCC cell lines. Moreover, LSAMP was also found to be methylated in 26 % of 
colorectal cancers by additional experiments.  In several tumors independent of 
methylation status loss of heterozygosity (LOH) of LSAMP was observed. Increasing 
expression of LSAMP in samples where it is methylated, had an inhibitory effect on 
cell proliferation which supported the hypothesis of LSAMP as a candidate tumor 
suppressor gene in CCRCCs (Chen et al., 2003). 
 
In a broad study investigating the status of IgLON family genes in epithelial ovarian 
cancer, LSAMP was shown to be a potential tumor suppressor gene in epithelial 
ovarian cancer (Ntougkos et al., 2005). Besides being differentially expressed 
between normal and tumor, LSAMP expression was also found to be associated with 
differentiation status as it is highly expressed in well or moderate tumors (Ntougkos 
et al., 2005) Among the IgLON family members, OPCML was also suggested as a 
tumor suppressor gene based on data obtained from epithelial ovarian cancer. 
Inactivation by LOH and hypermethylation was frequently observed in tumor  
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samples. Moreover, decreased expression and epigenetic inactivation of OPCML has 
been shown in brain tumors, multiple carcinomas and lymphomas (Cui et al., 2008; 
Reed et al., 2007) . 
 
Recently, two different groups identified LSAMP deletions in osteosarcomas (Kresse 
et al., 2009; Yen et al., 2009a). Kresse et al. (2009) showed that chromosomal region 
containing LSAMP gene is frequently deleted in osteosarcoma tumor samples and 
cell lines by using CGH array analysis. Moreover, at the expression level, low 
expression of LSAMP in tumors was shown to be correlated with poor survival 
(Kresse et al., 2009). Yen et al. (2009) also identified chromosomal aberrations in the 
region of 3q13.31 where LSAMP is located to be associated with progression of 
osteosarcomas. Homozygous or heterozygous deletions of LSAMP in primary 
osteosarcomas were detected and further supported with reduced expression levels of 
LSAMP in the same tumors (Yen et al., 2009b). 
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2 AIM:  
 
Clinical studies are not sufficient for good prognosis in advanced stages of 
neuroblastoma which has a poor survival. Elucidating the molecular biology of 
neuroblastoma is a crucial step for improved prognosis and therapies. Inactivation of 
one or more tumor suppressor gene(s) in a neuroblast cell has been proposed for the 
initial step of the neuroblastoma genesis. Identification of tumor suppressor genes 
has a great potential for revealing the mechanism of tumor development and further 
investigation of new therapeutic approaches. Previous efforts identified several 
genetic alterations that may be used as prognostic markers in neuroblastoma. Among 
these alterations the amplification of MYCN which is identified in 20% of the cases 
has been used widely since its detection as the first strong indicator of poor outcome. 
However, MYCN amplification or other aberrations are not enough in classifying 
patients into low or high risk groups because of the heterogeneity of neuroblastoma.  
 
Since neuroblastoma is neural crest originated, it is rational to inspect genes that 
drive neural development. IgLON family members (LSAMP, OPCML, NTM, and 
NEGR1) are well characterized for their function in developing neural system. 
Furthermore, they function as cell adhesion molecules whose roles in tumorigenesis 
are well established. Recently, several studies suggested two members of this family, 
LSAMP and OPCML, as potential tumor suppressors for epithelial ovarian cancer. 
Loss of OPCML is further associated with brain tumors. LSAMP is also linked to 
clear cell renal cell carcinoma and osteosarcomas. Moreover, homozygous deletions 
of LSAMP marker in neuroblastoma cell lines were shown. 
 
In the light of these data and necessitate for improving prognosis in neuroblastoma, 
this study aims to identify a novel candidate tumor suppressor; LSAMP, which we 
hypothesize to be a gene that plays a role in neuroblastoma tumorigenesis. 
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3 MATERIALS AND METHODS: 
3.1 Materials: 
3.1.1 Chemical Solutions and Reagents: 
 
Ethidium Bromide (EtBr): 
10mg/ml in water (stock solution)   
30ng/ml (working solution) 
 
50X TAE Buffer:  
121 g Tris Base 
28.55 ml Acetic Acid (Glacial)  
18.6 g Na2EDTA.H2O (Triplex) (Added in last step to ease dissolving) 
∆H2O is added to 500 ml. 
 
6X Loading Buffer: 
30%     Glycerol  
0.04%  Bromphenolblue  
0.04%  Xylene Cyanol  
∆dH2O 
 
2% (w/v) Agarose Gel: 
50 ml 1X TAE  
1 g Agarose (Prona, Basica Le Agarose) 
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10 mM TE Buffer: 
∆dH2O to 400 ml 
0.61 g Tris   
0.15 g EDTA (m.w. 292.1) 
∆dH2O to bring volume to 500 ml 
Adjust pH to 7.5 - 8.0 
 
10mM TE/1% Tween 20: 
1 ml Tween 20 is added into 100 ml of 10mM TE Buffer 
 
3.1.2  PCR Primers and Conditions: 
 
3.1.2.1 Semi-Quantitative and Multiplex PCR Reactions: 
 
3.1.2.1.1 Master Mix: 
 
PhireTM Hot Start DNA polymerase (F-120S) and DyNAzymeTM II DNA Polymerase 
(F-503S) were purchased from Finnzymes’s (Espoo, Finland) and were used in semi 
Q-PCR and Multiplex PCR reactions, respectively. Reaction buffers and MgCl2 
buffers provided with the DNA polymerases were used. dNTP mix (10 mM of each 
nucleotide) (#R0192) of Fermentas (Burlington, Canada) and HyClone HyPureTM 
Molecular Biology Grade Water produced by Thermo Scientific (Waltham, USA) 
were used in all reactions. Primers used in the study were synthesized by IONTEK 
(Istanbul, Turkey). 
 
3.1.2.1.2 Primers: 
 
Primers for LSAMP and GAPDH were designed by using Primer3 program available 
online at http://frodo.wi.mit.edu/. Intron – exon boundaries were used in design of 
LSAMPgnf54 and LSAMPex3r primer pairs which was used for amplifying only 
genomic DNA of 98 bp in neuroblastoma PCR reactions. LSAMPutrFrw and 
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LSAMPex7cdRev primer pairs were used in brain tumors with a product size of 
1167bp. A second primer pair LSAMPcdNstFrw and LSAMPcdNstRev were used 
further in Nested PCR reactions of brain tumors producing a band of 167 bp. 
GAPDH primers were designed for genomic amplifications and cover 143 bp. 
Designed primers were ordered from IONTEK (Istanbul, Turkey) and purchased in 
lyophilized form. All primers were hydrated to a concentration of 100 pm. The 
sequences of the primers are given in Table 2. 
 
 
Primer Name Sequence (5ʹ to 3ʹ) Product Size 
LSAMPgnf54 CCTGGAGACACCTTACACCAAC 
98bp 
LSAMPex3R ATTCAGCAGAATTCCAGGAGC 
LSAMPutrFrw CTGAGCGAGGGAAAGAGAGA 
1167bp 
LSAMPex7cdRev  AGAAGGCAGAGCAGAGATGC 
LSAMPcdNstFrw  CTCCAATATCTCCTCGGATGTC 
167bp 
LSAMPcdNstRev  GTGATGCCAAGGATCTCCAG 
GAPDH_GENOMIC_20070206_F ACACCCACTCCTCCACCTTT 
143bp 
GAPDH_GENOMIC_20070206_R CTGAGCCAGCCACCAGAG 
 
 
Table 2: Primers Used in PCR reactions 
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3.1.2.2  Quantitative Real Rime PCR (Q-RT-PCR) Reactions: 
 
3.1.2.2.1 Master Mix: 
 
For all Q-RT-PCR reactions master mix of Bio-Rad IQ SYBR Green Supermix 
(California, USA) was used. Reaction steps were performed according to the 
manufacturer’s instructions. Reaction conditions are listed in Table 7.1 & 7.2 in 
methods section under “Quantitative-RT-PCR Reaction” title. 
 
3.1.2.2.2 Primers: 
 
SybGREEN qPCR LSAMP primer mix was commercially purchased from Ori-Gene 
Company (Cat. no: HP206046). Primer sequences are not specified in respect to 
company’s confidentiality procedure. Primers are known to amplify a region around 
95 to 140 bp. Beta-actin gene (ACTB) was selected to use as internal control. 
 
3.1.2.2.3 Instrument: 
 
Stratagene Mx5000P (California, USA) instrument was used to perform Q-RT-PCR 
experiments. 
 
3.1.3 Tumor Samples: 
 
Neuroblastoma tumor samples and tissue sections were provided by Dr. Aylin Okçu 
Heper from School of Medicine, Department of Pathology, Ankara University. 6 
neuroblastoma patients provided research materials. 2 paraffin embedded tissue 
sections from each of 6 patients, 12 samples in total, and 14 poly-l lysine coated 
tissue slides were kindly provided. 12 samples and 8 tissue slides involving 6 tumors 
and 2 controls were used for protein level analysis of LSAMP (Table 3). 
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Tumor Samples  Tissue Sections 
12116-1  12116-1 
12116-2  12116-2 
28231-1  28231-1 
28231-2  28231-2 
3978-kon603006-1  3978-kon603006-1 
3978-kon603006-2  3978-kon603006-2 
3755-1  3755-1 
3755-2  3755-2 
13598-B3-1  13598-B3-1 
13598-B3-1  13598-B3-1 
1506-1  1506-1 
1506-2  1506-2 
  15194-1 
  15194-2 
  4914-1 
  4914-2 
 
Table 3: List of neuroblastoma tumor samples and tissue sections used in this study, 
two samples from each patient were provided 
 
 
Brain tumor samples of 37 patients with different types and grades of brain tumor 
and 3 normal brain tissues were kindly provided by Assoc. Prof. Hasan Uğur Çağlar 
from School of Medicine, Department of Neurosurgery, Ankara University (Table 4)  
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Type and Grade Brain Tumor Type and Grade Brain Tumor 
Oligodendroglioma O1 Glioblastoma G2 
Oligodendroglioma O4 Glioblastoma G4 
Oligodendroglioma O5 Glioblastoma G6 
Ependymoma E9 Glioblastoma G12 
Pilocytic Astrocytoma P12 Glioblastoma G13 
Astrocytoma3 A3/22 Glioblastoma G14 
Astrocytoma4 A4/41 Glioblastoma G16 
Astrocytoma4 A4/43 Glioblastoma G17 
Astrocytoma4 A4/49 Glioblastoma G18 
Astrocytoma4 A4/55 Glioblastoma G19 
Astrocytoma4 A4/56 Glioblastoma G20 
Astrocytoma4 A4/59 Glioblastoma G21 
Normal Brain NR/61 Glioblastoma G31 
Normal Brain NR/63 Glioblastoma G32 
Normal Brain NG63 Glioblastoma G33 
Meningioma M1 Glioblastoma G34 
Meningioma M5 Glioblastoma G36 
Meningioma M8 Glioblastoma G37 
Meningioma M9 Glioblastoma G40 
Meningioma M23 Glioblastoma G42 
 
Table 4: List of brain tumors of different types and grades used in this study 
 
3.1.4 Cell Culture: 
 
3.1.4.1 Cell Lines: 
 
Two frozen neuroblastoma cell lines SK-NAS and CLB-MA1 (LT) were obtained 
from Dr. Valérie Combaret of Oncologie Génétique Centre Léon Bérard, France. 
Cells were tested and mycoplasma free. Cell lines in cryotubes were immediately 
stored in liquid nitrogen tanks after their arrival in dry ice. 
 
3.1.4.2 Media and Solutions 
 
Two cell lines SK-NAS and CLB-MA1 (LT) were cultured in 25 ml flasks 
(Greigner-Bio) as monolayer. Cell lines were grown in RPMI-1640 (Biological 
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Industries) supplied with 10% FBS (Sigma), 50mg/ml penicillin / streptomycin and 
non-essential amino acids (Biochrom AG).  Cell lines were cultured at 37°C in an 
incubator with 5% CO2 (Heto-Holten, Surrey, UK).  Cells were handled in sterile 
laminar hoods (Heto-Holten, Surrey, UK).  Reagents were kept at 4°C except 
Trypsin – EDTA which was stored at -20 °C and pre-heated to 37°C before use.  
 
3.1.4.3 Antibody 
 
Rabbit polyclonal antibody to LSAMP (ab64427) was purchased from Abcam 
(Cambridge, USA).  
 
3.2 Methods: 
 
3.2.1 The cDNA Synthesis: 
 
RevertAidTM First Strand cDNA synthesis kit (#k1622) (Fermentas, USA) was used 
for all cDNA synthesis reactions. All reagents were provided by the kit. Total RNA 
samples isolated from brain tumor patients were reverse transcribed according to 
manufacturer’s protocol. 2 µg of RNA template was mixed with 1 µl oligodT and 
DEPC treated water is added to 12 µl. Mixture was gently pipetted and incubated at 
70°C for 5 minutes. After incubation 4 µl of 5X reaction buffer, 1 µl of RibolockTM 
Ribonuclease inhibitor and 2 µl of dNTP mixture were added in order. The mixture 
was gently pipetted and incubated at 37°C for 5 minutes. In next step, 1 µl of Revert 
Aid TM M-MuLV Reverse Transcriptase is added and incubated at 42°C for 1 hour 
proceeded by 10 minutes at 70°C. The products were stored at -20°C for further use. 
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3.2.2 Multiplex PCR Reaction: 
 
Multiplex PCR (MP-PCR) was performed by using genomic primers for LSAMP and 
GAPDH. All PCR reactions were carried out by using Techne-512 PCR machine 
(Techne Inc). Optimal conditions were obtained by changing primer concentrations 
and temperature. Reaction conditions and final concentrations of reagents used in 
master mix for one tube (25 µl) are listed in Table 5 and Table 6, respectively. 
Templates containing 100 ng or 200 ng of DNA were used in reactions. All resulting 
PCR products were assessed by running in 2% agarose gels with EtBr and visualized 
under UV. 
 
Reagent 
Stock 
Concentration 
Final 
Concentration 
Master 
Mix 
Setup 
Reaction Buffer 10 X 1 X 2.5 µl 
LSAMPgnf54 10 pm 0.4 pm 1 µl 
LSAMPex3R 10 pm 0.4 pm 1 µl 
GAPDH_GENOMIC_20070206_F 10 pm 0.15 pm 0.375 µl 
GAPDH_GENOMIC_20070206_R 10 pm 0.15 pm 0.375µl 
MgCl2 50 mM 1.5 mM 0.75 µl 
DyNAzymeTM II DNA Polymerase 2 U/µl 2 U 1 µl 
∆dH2O - - 
Add to 25 
µl* 
 
 
Table 5: MP-PCR master mix reagents and concentrations 
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Reaction Steps Cycle Numbers 
5 min. of initial denaturation at 95°C 
 
1 
30 sec. at 95°C 
 
35 30 sec. at 60°C 
 35 sec. at 72°C 
 
10 min. at 72°C 1 
 
 
Table 6: MP-PCR Reaction conditions 
 
3.2.3 Semi-Quantitative PCR Reaction: 
 
Brain tumor cDNAs were tested for LSAMP expression level by semi Q-PCR 
method. GAPDH was selected as a housekeeping gene before starting to experiments 
and all samples were tested for GAPDH expression. All PCR reactions were done in 
Techne-512 PCR equipment (Techne Inc). Optimal conditions were obtained by 
changing primer concentrations and temperature. Reaction conditions and final 
concentrations of reagents used in master mix for one tube (20 µl) are listed in Table 
7 and Table 8, respectively. All resulting PCR products were assessed by running in 
agarose gels with EtBr and visualized under UV. 
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Reagent 
Stock 
Concentration 
Final 
Concentration 
Master Mix 
Setup 
Reaction Buffer 5 X 1 X 4 µl 
LSAMP Forward Primer# 10 pm 0.5 pm 1 µl 
LSAMP Reverse Primer# 10 pm 0.5 pm 1 µl 
PhireTM Hot Start DNA 
polymerase  
- - 0.4 µl 
∆dH2O - - Add to 20 µl* 
 
Table 7: Semi-Q-PCR master mix reagents and concentrations 
 
 
Reaction Steps Cycle Numbers 
30sec. initial denaturation at 98°C 
 
1 
5 sec. at 98°C 
 
30 5 sec. at 63°C 
 20 sec. at 72°C 
 
1 min. at 72°C 1 
 
Table 8: Semi-Q-PCR Reaction conditions 
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3.2.4 Quantitative RT-PCR Reaction: 
 
SYBR Green I method recommended by manufacturer was applied for analysis of 
LSAMP expression in brain tumors and normal brain tissue. LSAMP primer mix and 
Beta-actin gene (ACTB) primers were purchased from OriGene and used in all 
reactions. Beta-actin gene was used as internal control. 37 tumor and 3 normal brain 
samples were tested in duplicates for both LSAMP and beta-actin gene (ACTB). 
Reaction mixture setup for one tube and conditions are listed in Table 9, 10 and 11. 
 
Corresponding readings of expression for both genes in tumors and normal samples 
were used in calculating expression differences (Table 12). The relative expression 
of LSAMP in tumors compared to normal brain tissues has been calculated by delta - 
delta CT method.  The formula used in these calculations is as below: 
 
• Relative Expression Ratio =  
      [E
 (LSAMP)  
∆Ct
LSAMP
(Ct normal - Ct tumor) / E (ACTB)  ∆CtACTB(Ct normal - Ct tumor) ]  
 
In this formula, E
 (LSAMP) and E (ACTB) represent the primer efficiencies of LSAMP and 
ACTB primers, respectively. Efficiency of the primers was approximated as 100% 
therefore a two fold increase at each cycle (E (LSAMP) = 2, E (ACTB) = 2). ACTB gene (B-
actin) was used as reference for normalization. Ct normal values correspond to Ct 
values of normal brain samples, where Ct tumor belongs to Ct values of brain 
tumors. Results were log2 transformed and plotted (Fig.11). Statistical analysis of 
significance was performed by using one sample t-test at 95% confidence interval 
(H0 = No difference exists in tumors compared to normal = 0). 
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Reaction Mixture  Volume 
2X  Master mix (Bio-Rad IQ ) 12.5 µl 
LSAMP primer mix 1 µl 
Template cDNA 1 µl 
dH2O 10.5 µl 
Mineral oil  12.5 µl 
Total 37.5 µl 
 
 
Table 9: Q-RT-PCR reaction mixture for LSAMP gene 
 
 
 
Reaction Mixture  Volume 
2X  Master mix (Bio-Rad IQ ) 12.5 µl 
Beta-actin forward primer (10pm) 1 µl 
Beta-actin reverse primer (10pm) 1 µl 
Template cDNA 1 µl 
dH2O 9.5 µl 
Mineral oil  12.5 µl 
Total 37.5 µl 
 
 
Table 10: Q-RT-PCR reaction mixture for beta-actin (ACTB) reference gene 
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Reaction Steps   Cycle Number 
5 min. of initial denaturation at 95°C  1 
15 sec. at 95°C  
40 15 sec. at 62°C 
15 sec. at 72°C 
10 min. at 72°C  1 
Melting Curve Step  
1 min. at 95 °C 
1 30 sec. at 55 °C 
30 sec. at 95 °C 
 
Table 11: Reaction setup in quantitative RT-PCR experiments 
 
3.2.5 Agarose Gel Electrophoresis  
 
2% agarose gels with 30ng/µl EtBr were prepared to run PCR products. 2µl of 6X 
DNA loading dye was added to 10µl of each PCR product and gently pipetted. 1X 
TAE buffer was added into gel electrophoresis equipment and gel tray was placed 
properly. Gene Ruler DNA Ladder Mix of Fermentas (100-10,000bp) (Burlington, 
Canada) was used as size marker and loaded into the first well. Samples were loaded 
into separate wells which are horizontally aligned and run vertically under 100 V for 
approximately 30 minutes. Visualization and photography of DNAs were carried out 
by using Bio-Rad (California, USA) Transilluminator equipment under UV light of 
340 nm wavelength.    
 
3.2.6 Thawing and Culturing Cell Lines 
 
 Cryotubes were removed from liquid nitrogen tanks and thawed at 37°C. Lids of the 
tubes were carefully loosened and pressure inside the tubes was decreased. The cells 
were resuspended gently by using a pipette and 5ml of growth medium pre-heated to 
37°C was added into each tube inside the sterile hood. The cells were centrifuged at 
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1500 rpm for 5 minutes. Supernatants were discarded and the pellets were 
resuspended in 5 ml growth medium to plate into 25 ml flasks. Flasks were stored in 
a humidified incubator at 37°C with 5% CO2.  Culture mediums were refreshed in 
the next day.  
 
3.2.7 Growth and Passaging of Cell Lines  
 
 Cells were examined under bright field microscope everyday for their confluency 
and culture mediums were refreshed. All culture mediums and enzymes were pre-
heated to 37°C. Inside the sterile hood, the old mediums were vacuumed and the 
cells were washed twice with PBS.  PBS was removed with vacuum and 0.5 ml of 
trypsin was added to each flask. Cells were incubated for 2-3 minutes at room 
temperature. Detachment of cells from the flask surface was confirmed via 
microscope and 5 ml of fresh RPMI 1640 (with supplements) medium was added to 
deactivate trypsin. Medium was pipetted gently to scatter cells from flask surface. 
Each cell line was divided into two by transferring 2.5 ml into new two 25 ml flask 
for each. 2.5 ml of medium was added into each bringing the total volumes to 5 ml. 
Flasks were kept in incubators at 37°C with 5% CO2.     
 
3.2.8 Pelleting and Collecting Cells 
 
The medium of flasks, where cells reached to optimal confluency, was aspirated and 
washed with PBS twice. 0.5 ml of trypsin was used for each flask to detach cells 
from the surface. Flasks were incubated at room temperature for 2-3 minutes. Fresh 
medium was supplied for each and gently pipetted. Suspensions were collected to 15 
ml falcon tubes and centrifuged at 1400 rpm for 5 minutes. Supernatants were 
discarded and the pellets were washed with PBS twice. Tubes were centrifuged again 
at 1400 rpm for 5 minutes and resulting supernatants were aspirated via vacuum 
carefully. Pellets were immediately kept at -80°C. 
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3.2.9 Genomic DNA Isolation  
 
Cell pellets were removed from -80°C refrigerator and thawed at room temperature. 
Qiagen DNeasy Tissue Kit (Venlo, The Netherlands) was used for isolating genomic 
DNA according to manufacturer’s recommended protocol. Nanodrop 
Spectrophotometer (Nanodrop Technologies) was used for assessing the quality and 
amount of genomic DNA extracted. Samples were stored at -20°C. 
 
3.2.10 Immunohistochemical Analysis of LSAMP Protein  
 
Immunohistochemistry (IHC) was performed on sections of 6 neuroblastoma, 1 fetal 
kidney & suprarenal and 1 adult cerebellum tissues. Neuroblastoma tissues from 
patients were sectioned on poly-l lysine coated slides and were provided by Dr. 
Aylin Okçu Heper from School of Medicine, Department of Pathology, Ankara 
University. Dr. Emin Öztaş from Gülhane Military Medical Academy (GMMA) 
helped us with the IHC protocol. In brief, tissue sections were deparaffinized at 70°C 
and then in Xylene. After rehydration in graded alcohol series, glass slides were 
immerged in 10 mM citrate buffer, pH 6.0 and transferred into microwave for 20 
minutes for antigen retrieval. Endogenous peroxidase was blocked by incubation of 
slides in 0.3 % H2O2 for 30 minutes. Phosphate buffered saline (PBS) was used in all 
washing steps. Tissue sections were incubated with LSAMP polyclonal antibody 
used at 1:500 dilutions in blocking solution, 50 µl was used for each slide. Slides 
were left overnight in humid chamber at 4 °C. Next day slides are washed with PBS 
and then universal staining kit (LabVision) was used according to manufacturer 
recommendations. Diaminobenzidine (DAB) was used as chromogen, and the slides 
were counterstained using Mayer’s haematoxylin. Normal serum or phosphate 
buffered saline were used as negative controls, instead of the primary antibodies. 
Both positive and negative controls were processed in the same slides which have 
two distinct regions of tissue sections. Regions close to the slide ID was used as 
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positive where regions at the terminal ends were used as negative. Dark brown 
staining in sections was taken as positive reaction.  
 
3.2.11 DNA extraction from Paraffin Embedded Tissues 
 
5 µm sections of 12 paraffin embedded tissue samples collected from neuroblastoma 
patients were provided by Dr. Aylin Okçu Heper from Ankara University, Medical 
School, Department of Pathology. The same patients studied for LSAMP expression 
by using IHC were chosen. Boiling method protocol of Cao et al (2003) was used for 
DNA extraction from paraffin embedded tissues (Cao et al., 2003). Briefly, 1 ml of 
Xylene was added into the eppendorfs containing paraffin sections. Tubes were 
inverted several times and incubated a few minutes at room temperature. The 
samples were centrifuged for 5 min at 13,000 rpm to pellet the tissue. After obtaining 
pellets, the two steps, adding Xylene and centrifugation, were repeated. The pellets 
were washed by adding 100% ethanol, the tubes were inverted several times and 
centrifuged as 13,000 rpm for 5 min. The supernatant was removed and the step was 
repeated. 1 ml of 10 mM TE buffer  was added into each tube and inverted several 
times before centrifuging at 13,000 rpm for 5 min. Supernatants were removed.    
100 µl of 10 mM TE/1% Tween 20 containing 200 µg proteinase K was added into 
each tube and left to incubation at 55°C overnight. Next day, the tubes were heated at 
97°C for 10 min to inactivate proteinase K and centrifuged at 13,000 rpm for 5 min. 
Supernatants were removed into new tubes and stored at - 20 °C. 
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4 RESULTS: 
 
4.1 Genetic Analysis of LSAMP Gene Region in Tumors and Cell 
Lines: 
 
Neuroblastoma genomic DNA was isolated from paraffin sections from 6 patients (2 
sections for each) and 2 neuroblastoma cell lines; SK-NA-S and CLB-MA1, were 
analyzed for LSAMP. Samples 13598-1, 13598-2, 3755-1, 3755-2 and 3978-2 did not 
result in amplifications for both genes (data not shown). GAPDH was used as 
reference gene and GAPDH primers were used in combination with LSAMP primers 
in Multiplex-PCR reactions. 2 HCC (hepatocellular carcinoma) samples, SKHep-1 
and Hep-3B, which have normal copy numbers of LSAMP, were used as positive 
controls. Products were loaded together with Gene Ruler DNA Ladder mix (100-
10,000 bp) in 2% agarose gels under constant voltage of 100V about 30 min. The 
expected product sizes for amplified LSAMP and GAPDH genomic regions were 
98bp and 143bp, respectively. Visualization with Bio-Rad Transilluminator, revealed 
the banding patterns corresponding to two genomic regions. Although, GAPDH was 
longer in base pairs, it was amplified in all samples, but LSAMP having smaller base 
pairs, which would be easier to amplify, was not detected to be fully amplified in a 
few samples. This suggested possible deletions in LSAMP genomic region in these 
samples. Thus, among 6 clinical patient samples, one possible homozygous deletion 
and one LOH in LSAMP region was identified. 
 
4.1.1 Homozygous Deletion of LSAMP Gene: 
 
Although amplification patterns of GAPDH region were similar for all patient 
samples, cell lines and controls, in patient #28231 any band corresponding to LSAMP 
gene could not detected which suggests a homozygous deletion of LSAMP genomic 
region (Fig.6).  
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Figure 6: Homozygous deletion of LSAMP region in patient #28231 is shown. 
Multiplex-PCR result of LSAMP and GAPDH in neuroblastoma tumor and cell lines 
where HCC samples SK-Hep-1 and Hep-3B were used as positive control.  
 
 
4.1.2 LOH at LSAMP Genomic Region: 
 
Although, there was a band corresponding to LSAMP genomic region in tumor 
sample of patient #12116, the intensity of the band was weaker compared to GAPDH 
band. This result may suggest a possible LOH in correspondent LSAMP 
chromosomal region 3q13.31 (Fig.7).       
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Figure 7: Possible LOH in LSAMP locus of patient sample #12116 is shown. Multiplex-
PCR result of LSAMP and GAPDH in neuroblastoma tumor and cell lines where HCC 
sample SK-Hep-1 was used as positive control.  
 
 
 
4.2 Assessment of LSAMP Protein in Neuroblastoma Tissues: 
 
6 neuroblastoma tissues sectioned from the same patients analyzed for any genomic 
aberrations in LSAMP gene were further assessed at the protein level. IHC was used 
to detect LSAMP protein in neuroblastoma tissues. Additionally, healthy adult 
cerebellum and fetal kidney & suprarenal tissues were used as positive controls. 
Pictures of successful staining were shot with Zeiss Axiocam Imager A1 microscope 
(Gottingen, Germany). We observed a common weak staining pattern for all tumor 
samples compared to positive controls. Moreover, consistent to the result of genomic 
analysis, we did not see any protein in patient sample #28231 (Fig.8). 
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Figure 8: LSAMP protein levels in neuroblastoma tissues revealed by IHC (A, B, C, D, 
E, and F).  Healthy adult cerebellum and fetal kidney &suprarenal tissue sections are 
used as controls (G & H). 
 
4.3 Analysis of LSAMP Expression in Brain Tumors: 
 
In addition to genomic and protein level analyses, we also assessed the expression of 
LSAMP in mRNA level in other tumors derived from neural tissues. A set of brain 
tumor patient RNAs were first reverse transcribed into cDNAs and tested for 
GAPDH gene levels which was used as reference gene in semi-quantitative PCR 
experiments (Fig.9 & Fig 10).  All samples were used in analysis of LSAMP 
expression with semi quantitative PCR and Q-RT-PCR methods. 
 
4.3.1 Semi Quantitative PCR Results: 
 
All brain tumor samples were first tested by using primer pairs designed for 
amplifying a large region involving 6 exons in LSAMP gene. Glioblastoma samples 
were successfully amplified (Fig.10). Meningioma, oligodendroglioma, astrocytoma, 
ependymoma and pilocytic astrocytoma samples were further analyzed in nested 
PCR reactions by using primer pairs designed for amplifying a smaller region inside 
the first amplification (Fig .11). 
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Figure 9: LSAMP and GAPDH expression levels of the same glioblastoma samples. 
 
 
 
 
 
 
 
 
 
LSAMP  
GAPDH 
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Figure 10: LSAMP expression in brain tumors; M series: Meningioma, O series: 
Oligodendroglioma, N series: Normal brain, P 12: Pilocytic Astrocytoma A series: 
Astrocytoma Grade 4, E9: Ependymoma. 
 
 
Results showed us in some tumors although GAPDH is well expressed, LSAMP 
expression was lower compared to normal brain samples. A table summarizing these 
results showed us there is particularly a difference of expression in astrocytoma 
grade 4, meningioma and glioblastomas (Table 12). In this table, weak intensity 
bands are represented by “+”, medium intensity by “++” and high intensity by “+++” 
signs. Although, semi quantitatively we observe the decrease in LSAMP expression, 
a more precise method Q-RT-PCR was performed in next step for detecting actual 
expression levels. 
 
4.3.2 Q-RT-PCR Detection of LSAMP Expression in Brain Tumors: 
 
We performed Q-RT-PCR experiments by using commercially obtained LSAMP 
primers amplifying a small region between 100-140bp and Βeta-actin primers to use 
Beta-actin expression as control. BioRad SyBr Green Kit was used to prepare master  
LSAMP
GAPDH 
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mix. The results were analyzed by using delta - delta Ct method and indicate a clear 
decrease in LSAMP expression in majority of meningiomas, astrocytoma grade 4 and 
glioblastoma tumors compared to normal brain tissue (Table. 13, Fig.11).  
 
The calculated fold changes suggesting LSAMP has generally lower values for 
tumors compared to normal seem statistically significant at 95% confidence interval 
(p-value=0.002).
41 
 
 
Type and Grade Brain Tumor LSAMP GAPDH Type and Grade Brain Tumor LSAMP GAPDH 
Oligodendroglioma O1 No +‡ Glioblastoma G4 No + 
Oligodendroglioma O4 +++ +++ Glioblastoma G6 + +++ 
Oligodendroglioma O5 +++ ++ Glioblastoma G12 +‡ +++ 
Ependymoma E9 ++ ++‡ Glioblastoma G13 +++ +++ 
Pilocytic Astrocytoma P12 No +‡ Glioblastoma G14 + ++ 
Astrocytoma3 A3/22 No + Glioblastoma G16 +++ +++ 
Astrocytoma4 A4/41 ++ +++ Glioblastoma G17 No + 
Astrocytoma4 A4/43 ++ +++ Glioblastoma G18 + + 
Astrocytoma4 A4/49 + +++ Glioblastoma G19 +++ +++ 
Astrocytoma4 A4/55 +++ +++ Glioblastoma G20 No ‡ 
Astrocytoma4 A4/56 +++ +++ Glioblastoma G21 +++ +++ 
Astrocytoma4 A4/59 + +++ Glioblastoma G31 No +++ 
Normal Brain NR/61 ++ +++ Glioblastoma G32 +++ +++ 
Normal Brain NR/63 + +++ Glioblastoma G33 +++ +++ 
Normal Brain NG3 +++ +++ Glioblastoma G34 + +++ 
Meningioma M1 No +++ Glioblastoma G36 +++ +++ 
Meningioma M5 No ++‡ Glioblastoma G37 +++ +++ 
Meningioma M8 ++ +++ Glioblastoma G40 No + 
Meningioma M9 No ++‡ Glioblastoma G42 No ++ 
Meningioma M23 No ++ Glioblastoma G42 No ++ 
Glioblastoma G2 ++ ++ Glioblastoma G42 No ++ 
Table 12: The relative expression levels of LSAMP and GAPDH in different types and grades of brain tumors revealed by semi quantitative PCR 
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TumorSamples Ct LSAMP* CtACTB** Fold Change LOG2 
A322 30.62 30.2 0.737774 -0.43875 
A441 23.735 16.9925 0.009219 -6.76125 
A443 22.395 14.9 0.005472 -7.51375 
A449 24.555 19.935 0.040142 -4.63875 
A455 20.39 14.905 0.02204 -5.50375 
A456 19.025 15.19 0.069168 -3.85375 
A459 23.125 24.74 3.023564 1.59625 
E9 22.515 24.085 2.93071 1.55125 
G12 27.13 17.83 0.001566 -9.31875 
G13 23.365 17.035 0.01227 -6.34875 
G14 26.23 22.625 0.081123 -3.62375 
G16 24.16 18.54 0.020071 -5.63875 
G17 27.075 29.395 4.928846 2.30125 
G18 27.165 27.25 1.046992 0.06625 
G19 23.595 18.335 0.02576 -5.27875 
G2 25.01 19.275 0.018533 -5.75375 
G20 30.025 31.59 2.92057 1.54625 
G21 22.48 17.34 0.027994 -5.15875 
G31 24.695 24.725 1.007828 0.01125 
G32 24.53 18.57 0.015857 -5.97875 
G33 23.405 17.47 0.016134 -5.95375 
G34 25.345 20.22 0.028286 -5.14375 
G36 22.94 17.24 0.018988 -5.71875 
G37 24.525 17.58 0.008011 -6.96375 
G4 29.09 30.38 2.413706 1.27125 
G40 27.83 24.09 0.073876 -3.75875 
G42 26.265 23.435 0.138816 -2.84875 
G6 28.36 20.04 0.003089 -8.33875 
M1 26.77 24.955 0.280534 -1.83375 
M23 30.73 21.495 0.001638 -9.25375 
M5 23.71 19.595 0.056966 -4.13375 
M8 26.485 17.455 0.001888 -9.04875 
M9 27.205 21.38 0.017412 -5.84375 
O1 28.415 25.325 0.115924 -3.10875 
O4 21.735 19.965 0.289423 -1.78875 
O5 23.695 24.0875 1.295716 0.37375 
P12 26.895 28.735 3.533873 1.82125 
 
Table 13: Quantitative RT-PCR results of LSAMP in brain tumors 
(*Ct normal brain LSAMP: 23.0363, ** Ct normal brain ACTB: 23.055)
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Figure 11: Expression differences in brain tumors relative to normal brain tissue. 
Astrocytoma, Ependymoma, Glioblastoma, Meningioma, Oligodendroglioma, Pilocytic Astrocytoma 
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5 DISCUSSION: 
 
Risk stratification is a crucial step in prognosis of tumors and in the case of 
neuroblastoma, the most common extracranial solid tumor in children, it is far more 
important because of the heterogeneous nature of the tumor . Clinical studies showed 
that the good prognosis is highly correlated with increased survival in neuroblastoma 
patients. Therapeutic applications are needed to be performed in accordance with the 
stage of neuroblastoma for successful results. The unexplained behavior of the 
disease in different sub groups may result in ineffective therapies. Clinical 
observations alone are not successful to determine risk groups for many cases and the 
importance of genetic research in neuroblastoma emerged in recent years. 
Researchers have been focused on elucidating the molecular biology of 
neuroblastoma development to find potential tumor markers for improved prognosis 
and to answer the heterogeneous behavior of the disease. Analysis of patients 
revealed some genetic abnormalities that are seen frequently in most cases like 
MYCN amplification, 1p deletion and 17 q gain.  Furthermore, translocation and 
methylation events of important regulator genes are observed for a number of cases 
(Maris and Matthay, 1999).  However, the exact mechanism of tumor development is 
still unanswered and a model of neuroblastoma tumorigenesis via three different 
pathways has been hypothesized (Fig.3).  
 
As a typical event observed in carcinogenesis, inactivation of a tumor suppressor 
gene in a neuroblast cell has been proposed for the initial step of the neuroblastoma 
development. Thus, identification of tumor suppressor genes has a great potential for 
revealing the mechanism of tumor development and further investigation of new 
therapeutic approaches. Compared to the current therapies involving surgery and 
radiation, specific gene targeted approaches would be more efficient and less 
destructive. Several ways exist which result in chromosomal aberrations that 
deactivate tumor suppressors such as deletions, mutations and epigenetic 
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modifications. Moreover, certain types of aberrations in chromosomal regions may 
be used as a characteristic marker of the tumors which results in better prognosis. 
 
In this study, LSAMP was assessed as a potential tumor suppressor gene for 
neuroblastoma by using semi-quantitative PCR and IHC methods. PCR method was 
chosen for quick and accurate evaluation of LSAMP gene dosage in neuroblastoma 
tissue samples and cell lines where IHC was preferred for protein analyses in tissue 
sections. Among analyzed 12 samples, a total of 4 samples were identified as having 
LSAMP homozygous and heterozygous deletions compared to GAPDH internal 
controls and positive controls of SKHep-1 and Hep-3B (Table 14). However, the 
heterozygous banding pattern of the two samples might be due to the amplification of 
surrounding normal tissue genomic DNA.  
 
 
Sample ID Loss Sample ID Loss 
12116-1 LOH 1506 -1 None 
12116-2 LOH 1506 -2 None 
28231-1 Homo. Del. 3755-1 None 
28231-2 Homo. Del. 3755-2 None 
3978-1 None SK-NA-S None 
3978-2 None CLB-MA1 None 
13598-B3 -1 None SK-Hep-1 None 
13598-B3 -2 None Hep-3B None 
 
 
Table 14: Multiplex-PCR analysis of LSAMP in neuroblastoma tissues showing 
possible deletions 
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IHC was performed by using rabbit polyclonal LSAMP antibody on neuroblastoma 
tissue sections obtained from same patients whose DNA was used for PCR 
experiments. IHC experiments showed us localized weakly stained areas for LSAMP 
protein in all of the samples. Two samples were used as positive controls where 
LSAMP is known to be well expressed. Samples 15194 (adult cerebellum) and 4914 
(fetal kidney & suprarenal) revealed broader and stronger staining patterns compared 
to the tumor samples. Among tumor samples, 1506 and 3978 showed a stronger 
positivity compared to others (Fig.8).   
 
Both genomic analysis and protein analysis suggests that there may be an association 
with LSAMP and neuroblastoma. Furthermore, the two results can be compared and a 
correlation may be established between patients that have genomic deletions of 
LSAMP also have lower protein expressions compared to patients with no loss.  
 
An interesting result is that although LSAMP is known as a membrane protein, the 
staining pattern of the samples suggests a possible role of LSAMP also in cytoplasm. 
This observation may be correlated to the mechanism of IgLONs forming 
heterodimers with each other, a structure called “Diglon” (Reed et al., 2004). 
LSAMP might be dimerizing with OPCML, NEGR1 or NTM in cytoplasm and then 
functionally inserted into the plasma membrane. Also the existence of LSAMP 
isoforms with different functions yet unknown might be the result of staining spread 
through the cells. The formation of Diglons may suggest checking for other IgLON 
members in neuroblastoma since deletion of LSAMP may also affect the function of 
other IgLONs and consequently the signaling pathways they are responsible for. The 
positive correlation between IgLON family members was previously described for 
epithelial ovarian carcinoma where LSAMP, OPCML and NEGR1 were decreased in 
expression coordinately. Moreover, LSAMP has been also declared for a strong 
predictor of poor outcome in epithelial ovarian cancers (Ntougkos et al., 2005). 
 
 
47 
 
 
Originating from the sympathetic nervous system, tumors may develop in any site in 
the lineage like adrenal medulla which is the most common region. LSAMP, as the 
name indicates, is tightly associated with limbic system and sympathetic system. It is 
highly expressed along the nervous system and plays an important role during neural 
development. Tumor suppressor genes are generally classified into two groups as 
some tumor suppressors are specific to certain tissues while some of them act as a 
tumor suppressor in multiple types of cancer arising from the same lineage. Thus, 
possible tumor suppressor function of LSAMP may also exist in brain tumors as well 
as neuroblastoma. We performed semi-quantitative PCR and Q-RT-PCR analyses for 
LSAMP in a set of brain tumors with different types and grades. In a majority of the 
samples tested, downregulation of LSAMP compared to normal brain was observed. 
Semi-quantitative and quantitative results were also found to be generally in 
accordance with each other. In a previous study Reed et.al (2007) also identified 
OPCML downregulation in brain tumors (Reed et al., 2007). Taken together, these 
two correlated results suggested LSAMP to be an important regulator in neural 
system tumors and a possible tumor suppressor for neural tumors (Fig.9, 10, 11 and 
Table 12).  
 
OPCML were shown to be inactivated via LOH and CpG island methylation in 
epithelial ovarian carcinoma (Sellar et al., 2003). Inducing expression of OPCML in 
cell lines resulted in decreased proliferation and enhanced aggregation, which imply 
for a potential tumor suppressor role. 
 
LSAMP was also shown to be deleted and epigenetically inactivated in CCRCC 
(Chen et al., 2003). Furthermore, inducing expression of fluorescently tagged 
LSAMP in cell lines suppressed cell proliferation and resulted in growth inhibition. 
Similarly, two recent studies declared LSAMP as a tumor suppressor for 
osteosarcomas revealed by SNP and CGH arrays (Kresse et al., 2009; Yen et al., 
2009b) . In both cases, frequent homozygous and heterozygous deletions in 
chromosome region 3q13.31 were recorded and the low expression of LSAMP was 
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shown to be correlated with poor outcome (Kresse et al., 2009; Yen et al., 2009b). In 
the outcome data of Kresse et al., a positive association of LSAMP and OPCML was  
Also shown. In 7 of 9 tumor samples and 5 of 10 cell lines inspected, both 
chromosomal regions 3q13.31 and 11q25 of OPCML were deleted (Kresse et al., 
2009).  
 
In consequence, despite the high expression of not only LSAMP but also IgLON 
family members in neural tissues, their role in neural system tumors have not been 
researched in detail. The accumulating data associating them to different cancer 
types via LOHs and epigenetic modifications support the model of tumor suppressor 
inactivation in carcinogenesis. There is a high possibility that these genes are also 
inactivated in neuroblastoma as suggested by this study for LSAMP and their 
potential dimerization with each other. We observed heterozygous and homozygous 
deletions were observed in 2 of 6 clinical cases analyzed and in addition decreased or 
lost protein expressions compared to controls in all 6 samples were detected. 
Moreover, our data from genomic and protein analyses were found to be consistent 
with each other. LSAMP was also found to be downregulated in tumors derived from 
neural linage. All of these results suggest LSAMP may be a tumor suppressor in 
neural tumors and loss of LSAMP may be used as a marker. In this manner promising 
results of this study provides a preliminary step for further inspection of LSAMP and 
other IgLONs in neuroblastoma and other neural system tumors.  
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6 Future Perspectives: 
 
Although, a potential tumor suppressor role of LSAMP was observed in this study 
and suggested by data in literature, it would be wise to conduct further experiments 
for confirmation of the results. As a first step to confirm deletions, using advanced 
techniques like PCR amplification of polymorphic markers following capillary 
electrophoresis and CGH arrays can produce more detailed analysis revealing any 
genomic variations in the samples by comparing to normal tissues. 
 
As a common event observed in tumor suppressor inactivation during tumorigenesis, 
epigenetic modifications in the LSAMP promoter would be responsible for its 
decreased protein levels in samples we tested. Methylation status can be checked by 
performing methylation specific PCR reactions, easily.  
 
A further step to evaluate LSAMP as a tumor suppressor would be functional analysis 
in cell lines. The affect of LSAMP expression in cell lines would provide us valuable 
and strong data about its function in tumorigenesis. LSAMP expression can be 
induced by using expression vectors for cell lines and any inhibitory effect can be 
recorded. Moreover, at the protein level cellular expression and localization of 
LSAMP can be tracked via the use of fluorescent tags like GFP.   
 
The sample size of the experiments may be increased for increasing the statistical 
significance of the data. We could not study expression of LSAMP in neuroblastoma 
because of the lack in patient samples. Obtaining these cDNAs from neuroblastoma 
patients and Q-RT-PCR analysis of expression in different grades of tumor would be 
also valuable.  In order to find a correlation of LSAMP and different neuroblastoma 
stages, the samples from different stages should be used to detect its association to 
good or poor outcome .Other genomic aberrations may also have a negative or  
50 
 
 
positive correlation to LSAMP deletions. The genomic status of different factors like 
MYCN amplification status should be checked together for better assessment of 
LSAMP gene in neuroblastoma.   
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